ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
ORIC Pharmaceuticals, Inc. will participate in a fireside chat at the Citi 2024 Virtual Oncology Leadership Summit on February 21, 2024. The company focuses on developing treatments for therapeutic resistance in oncology.
02/14/2024 - 04:30 PM
SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 3:00 p.m. ET.
A live webcast of the discussion will be available through the investor section of the company’s website at www.oricpharma.com
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com X LinkedIn
Contact: dominic.piscitelli@oricpharma.com info@oricpharma.com
When will ORIC participate in the fireside chat at the Citi 2024 Virtual Oncology Leadership Summit?
ORIC will participate in the fireside chat on February 21, 2024, at 3:00 p.m. ET.
What is ORIC Pharmaceuticals, Inc.'s focus in terms of drug development?
ORIC is focused on developing treatments that address mechanisms of therapeutic resistance in oncology.
Where can investors watch the live webcast of the discussion?
Investors can watch the live webcast through the investor section of ORIC's website at www.oricpharma.com.
For how long will the replay of the webcast be available?
The replay of the webcast will be available for 90 days following each event.
ORIC Rankings
#86 Ranked by Stock Gains
ORIC Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
South San Francisco
About ORIC
oric pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. its lead product candidate is oric-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. the company's second product candidate is oric-533, an orally bioavailable small molecule inhibitor of cd73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. it is also developing multiple precision medicines targeting other cancer resistance mechanisms. the company was founded in 2014 and is headquartered in south san francisco, california.
